4.7 Review

How should we use convalescent plasma therapies for the management of COVID-19?

Journal

BLOOD
Volume 137, Issue 12, Pages 1573-1581

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020008903

Keywords

-

Categories

Funding

  1. National Health and Medical Research Council, Australia [1177784]
  2. Clinical Research Fellowship from the Victorian Cancer Agency
  3. National Health and Medical Research Council of Australia [1177784] Funding Source: NHMRC

Ask authors/readers for more resources

Convalescent plasma from blood donors with antibodies to SARS-CoV-2 may benefit COVID-19 patients by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal characteristics, transfusion volume, and administration timing remain to be determined, requiring international collaborative efforts to establish clinical efficacy. Preliminary safety data for COVID-19 CP is encouraging, with ongoing large, high-quality randomized trials starting to report preliminary results.
Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available